LJ TRUST Co LLC Holds Stake in Amgen Inc. (AMGN)
LJ TRUST Co LLC held its position in shares of Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 90,650 shares of the medical research company’s stock at the end of the first quarter. Amgen accounts for approximately 2.0% of LJ TRUST Co LLC’s holdings, making the stock its 9th largest position. LJ TRUST Co LLC’s holdings in Amgen were worth $14,873,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. TrimTabs Asset Management LLC increased its stake in Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the last quarter. Alpha Omega Wealth Management LLC increased its stake in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. increased its stake in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the last quarter. American Beacon Advisors Inc. purchased a new stake in Amgen during the first quarter worth approximately $106,000. Finally, Nelson Roberts Investment Advisors LLC purchased a new stake in Amgen during the first quarter worth approximately $121,000. Institutional investors own 79.12% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 1.27% during trading on Wednesday, hitting $172.20. 477,177 shares of the stock traded hands. The firm has a 50 day moving average price of $174.35 and a 200-day moving average price of $167.93. The company has a market cap of $125.65 billion, a PE ratio of 15.68 and a beta of 1.35. Amgen Inc. has a one year low of $133.64 and a one year high of $184.21.
Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.84 EPS. Analysts anticipate that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be issued a $1.15 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 annualized dividend and a yield of 2.71%. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
A number of analysts have recently commented on the company. UBS AG restated a “neutral” rating and set a $174.00 price objective (down from $175.00) on shares of Amgen in a report on Monday, May 22nd. Mizuho set a $195.00 price objective on Amgen and gave the stock a “buy” rating in a report on Saturday, May 6th. Cowen and Company restated an “outperform” rating and set a $209.00 price objective on shares of Amgen in a report on Wednesday, April 19th. BMO Capital Markets restated a “buy” rating and set a $198.00 price objective (down from $200.00) on shares of Amgen in a report on Monday, May 22nd. Finally, Morgan Stanley upped their price objective on Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, June 13th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $186.64.
In related news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.